Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 72.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 5.97% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.22% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -94.22% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 2,287.50% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -15.38% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -407.69% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -300.00% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 76.47% |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 215.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,287.50% |
| Dec 31, 2025 | 48.00% |
| Sep 30, 2025 | 64.52% |
| Jun 30, 2025 | 68.25% |
| Mar 31, 2025 | -80.95% |
| Dec 31, 2024 | -31.51% |
| Sep 30, 2024 | 51.22% |
| Jun 30, 2024 | -33.68% |
| Mar 31, 2024 | 153.16% |
| Dec 31, 2023 | 64.04% |
| Sep 30, 2023 | 18.84% |
| Jun 30, 2023 | 627.78% |
| Mar 31, 2023 | -664.29% |
| Dec 31, 2022 | 1,371.43% |
| Sep 30, 2022 | 200.00% |
| Jun 30, 2022 | -141.86% |
| Mar 31, 2022 | -57.58% |
| Dec 31, 2021 | -101.96% |
| Sep 30, 2021 | 137.10% |
| Jun 30, 2021 | -46.91% |